

Contents

Foreword by Gerald Healy	vii
Foreword by K.J. Lee	ix
Acknowledgments	xi
Contributors	xxiii

Section I Introduction

1 Introduction to Evidence-Based Medicine, Levels of Evidence, and Systematic Reviews	3
<i>Jennifer J. Shin and Christopher J. Hartnick</i>	
2 How to Use This Book	13
<i>Jennifer J. Shin and Gregory W. Randolph</i>	
3 English Translations of Statistical Terms, Study Designs, and Methods of Analysis	19
<i>Jennifer J. Shin, Christopher J. Hartnick, and Sandra S. Stinnett</i>	

Section II Systematic Reviews in Pediatric Otolaryngology

4 Pediatric Tonsillectomy	35
• 4.A. Tonsillectomy versus no surgery: Impact on number of recurrent throat infections or sore throats.	35
<i>Jennifer J. Shin and Christopher J. Hartnick</i>	
• 4.B. Postoperative systemic antibiotics: Impact on postoperative pain.	40
<i>Jennifer J. Shin and Christopher J. Hartnick</i>	
• 4.C.1. Single-dose systemic dexamethasone: Impact on postoperative emesis and oral intake	45
<i>Jennifer J. Shin and Christopher J. Hartnick</i>	
• 4.C.2. Single-dose systemic dexamethasone: Impact on postoperative pain.	49
<i>Jennifer J. Shin and Christopher J. Hartnick</i>	
• 4.D.1. Preoperative coagulation screening tests versus no laboratory testing: Impact on rate of intraoperative/postoperative bleed.	56
<i>Jennifer J. Shin and Christopher J. Hartnick</i>	
• 4.D.2. Preoperative coagulation screening tests: Predictive value for intraoperative/postoperative bleeding and for identification of occult bleeding disorders.	57
<i>Jennifer J. Shin and Christopher J. Hartnick</i>	
5 Pediatric Obstructive Sleep Apnea	63
• 5.A. Tonsillectomy and/or adenoidectomy: Impact on polysomnogram	63
<i>Mark Boseley and Christopher J. Hartnick</i>	
• 5.B. Tonsillectomy and/or adenoidectomy: Impact on quality of life.	68
<i>Mark Boseley and Christopher J. Hartnick</i>	

6	Pediatric Recurrent Acute Otitis Media	73
•	6.A. Amoxicillin or ampicillin prophylaxis versus placebo: Impact on number of subsequent episodes of acute otitis media, chance of no further episodes of acute otitis media	73
	<i>Jennifer J. Shin, Sandra S. Stinnett, and Christopher J. Hartnick</i>	
•	6.B. Sulfisoxazole prophylaxis versus placebo: Impact on number of subsequent episodes of acute otitis media, chance of no further episodes of acute otitis media	81
	<i>Jennifer J. Shin, Sandra S. Stinnett, and Christopher J. Hartnick</i>	
•	6.C. Amoxicillin versus trimethoprim sulfamethoxazole prophylaxis: Impact on number of subsequent episodes of acute otitis media, chance of no further episodes of acute otitis media	88
	<i>Jennifer J. Shin and Christopher J. Hartnick</i>	
•	6.D. Tympanostomy tube placement versus no surgery/no prophylaxis: Impact on subsequent number of episodes of acute otitis media, chance of no further episodes of acute otitis media	91
	<i>Jennifer J. Shin, Sandra S. Stinnett, and Christopher J. Hartnick</i>	
•	6.E. Tympanostomy tube insertion versus antibiotic prophylaxis: Impact on subsequent number of episodes of acute otitis media, chance of no further episodes of acute otitis media	98
	<i>Jennifer J. Shin and Christopher J. Hartnick</i>	
•	6.F. Adenoidectomy versus no adenoidectomy: Impact on rate of acute otitis media	103
	<i>Jennifer J. Shin and Christopher J. Hartnick</i>	
•	6.G. Adenotonsillectomy versus adenoidectomy alone or no adenotonsillar surgery: Impact on rate of acute otitis media	110
	<i>Jennifer J. Shin and Christopher J. Hartnick</i>	
7	Pediatric Otitis Media with Effusion	115
•	7.A.i. Amoxicillin versus placebo: Chance of becoming effusion-free	115
	<i>Jennifer J. Shin and Michael J. Cunningham</i>	
•	7.A.ii. Amoxicillin/clavulanate versus placebo: Chance of becoming effusion-free	122
	<i>Jennifer J. Shin and Michael J. Cunningham</i>	
•	7.A.iii. Cephalosporin versus placebo: Chance of becoming effusion-free	127
	<i>Jennifer J. Shin and Michael J. Cunningham</i>	
•	7.A.iv. Erythromycin versus placebo: Chance of becoming effusion-free	132
	<i>Jennifer J. Shin and Michael J. Cunningham</i>	
•	7.A.v. Trimethoprim-sulfamethoxazole versus control: Chance of becoming effusion-free	137
	<i>Jennifer J. Shin and Michael J. Cunningham</i>	
•	7.B. Tympanostomy tube placement: Impact on quality of life	145
	<i>Jennifer J. Shin and Christopher J. Hartnick</i>	
•	7.C. Adenoidectomy versus no surgery: Impact on resolution, improvement, and audiometry	151
	<i>Grace Chan, Jennifer J. Shin, and Margaret Kenna</i>	

• 7.D. Adenoidectomy versus tube placement: Impact on resolution, improvement, and audiometry	159
<i>Grace Chan, Jennifer J. Shin, and Margaret Kenna</i>	
• 7.E. Adenoidectomy with tube placement versus tubes alone: Impact on resolution, improvement, and audiometry	164
<i>Grace Chan, Jennifer J. Shin, and Margaret Kenna</i>	
8 Pediatric Sinusitis	171
• 8.A. Antibiotics/conservative treatment versus control for pediatric nonacute sinusitis: Impact on post-treatment clinical examination and imaging results.	171
<i>Manali Amin and Mark Volk</i>	
• 8.B. Adenoidectomy for pediatric chronic sinusitis refractory to antibiotic therapy: Impact on patient-reported symptoms and clinical evaluation	178
<i>Manali Amin and Mark Volk</i>	
• 8.C. Endoscopic sinus surgery for chronic/recurrent pediatric sinusitis: Chance for subjective and objective improvement	184
<i>Manali Amin and Mark Volk</i>	
9 Pediatric Cochlear Implantation.	197
• 9.A. Cochlear implantation in children with or without a history of frequent otitis media: Chance of post-implant acute otitis media and complications.	197
<i>Jennifer J. Shin and Margaret Kenna</i>	
• 9.B. Implantation of children with cochleovestibular anomalies versus normal anatomy: Impact on postoperative speech perception and complications	204
<i>Jennifer J. Shin and Margaret Kenna</i>	
10 Subglottic Stenosis	213
• 10.A. Single- versus double-stage laryngotracheal reconstruction: Rate of decannulation, need for subsequent procedures	213
<i>Jennifer J. Shin and Christopher J. Hartnick</i>	
• 10.B. Cricotracheal resection: Chance of decannulation, chance of undergoing subsequent salvage procedure.	219
<i>Jennifer J. Shin and Christopher J. Hartnick</i>	

Section III Systematic Reviews in Otology

11 Measuring Audiometric Outcomes.	227
<i>Christopher F. Halpin</i>	
12 Chronic Otitis Media	239
• 12.A. Topical antibiotic versus placebo or antiseptic alone for chronic active otitis media without cholesteatoma: Impact on resolution of otorrhea.	239
<i>Jennifer J. Shin and J. Gail Neely</i>	

• 12.B. Topical versus systemic antibiotic therapy for chronic active otitis media without cholesteatoma: Impact on resolution of otorrhea	250
<i>Jennifer J. Shin and J. Gail Neely</i>	
• 12.C. Topical versus combined topical and systemic antibiotic therapy for chronic active otitis media without cholesteatoma: Impact on resolution of otorrhea	255
<i>Jennifer J. Shin and J. Gail Neely</i>	
• 12.D. Otological neomycin: Impact on post-treatment hearing	259
<i>Jennifer J. Shin, Ming-Yee Lin, and Steven D. Rauch</i>	
• 12.E. Staging in tympanoplasty: Impact on audiometric outcomes	266
<i>Jennifer J. Shin and Saumil Merchant</i>	
13 Sudden Sensorineural Hearing Loss	273
• 13.A. Systemic steroids versus control: Impact on audiometric outcomes	273
<i>Jennifer J. Shin and Steven D. Rauch</i>	
• 13.B. Acyclovir adjunct to steroids versus placebo adjunct to steroids: Impact on audiometric outcomes	279
<i>Jennifer J. Shin and Steven D. Rauch</i>	
• 13.C. Valcyclovir adjunct to steroids: Impact on audiometric outcomes	285
<i>Jennifer J. Shin and Steven D. Rauch</i>	
• 13.D. Intratympanic steroids: Impact on audiometric outcomes	290
<i>Jennifer J. Shin and Steven D. Rauch</i>	
14 Cochlear Implantation	293
• 14.A. Comparative implant performance in postlingually deafened adults: Speech recognition outcomes	293
<i>Pamela Roehm, Richard S. Tyler, Camille Dunn, and Bruce J. Gantz</i>	
• 14.B. Cochlear implantation of prelingually deafened adults: Speech recognition outcomes	298
<i>Pamela Roehm, Richard S. Tyler, Camille Dunn, and Bruce J. Gantz</i>	
• 14.C. Implantation of adults: Impact on quality of life	303
<i>Steven Hemmerdinger and Susan Waltzman</i>	
• 14.D. Implantation of older adults: Speech recognition outcomes	308
<i>Rita M. Roure and J. Thomas Roland</i>	
• 14.E. Post-implant surgical-site infection: Management with antibiotics, nonexplant surgery, or explantation	314
<i>Rita M. Roure and J. Thomas Roland</i>	
• 14.F. Cochlear implantation: Risk of postoperative meningitis	319
<i>Rita M. Roure and J. Thomas Roland</i>	
15 Ménière Disease	325
• 15.A.i. Intratympanic gentamicin: Impact on vestibular complaints	325
<i>Ching Anderson and John P. Carey</i>	
• 15.A.ii. Intratympanic gentamicin: Impact on audiometry	331
<i>Ching Anderson and John P. Carey</i>	

• 15.B.i. Endolymphatic shunt surgery versus “sham” surgery or medical therapy: Impact on control of vertigo	335
<i>Walter Kutz and William H. Slattery III</i>	
• 15.B.ii. Endolymphatic shunt surgery versus “sham” surgery or medical therapy: Impact on audiometry	342
<i>Walter Kutz and William H. Slattery III</i>	
• 15.C. Surgical labyrinthectomy versus other procedures: Chance of decreased vestibular complaints	347
<i>Walter Kutz and William H. Slattery III</i>	
16 Tinnitus	351
• 16.A. Antidepressant agents versus placebo for idiopathic subjective tinnitus: Impact on symptom control	351
<i>Josh Finnell and Jay E. Piccirillo</i>	
• 16.B. Anticonvulsant agents versus placebo for idiopathic subjective tinnitus: Impact on symptom control	356
<i>Josh Finnell and Jay E. Piccirillo</i>	
• 16.C. Tinnitus retraining therapy: Impact on loudness, annoyance, and habituation to tinnitus	360
<i>Carol Bauer and Thomas J. Brozoski</i>	
• 16.D. Lidocaine versus placebo: Impact on loudness and annoyance of tinnitus	365
<i>Carol Bauer and Alison Perring</i>	
17 Bell’s Palsy	369
• 17.A. Systemic steroids alone versus placebo: Impact on recovery to normal or near-normal function	369
<i>Mitchell Ramsey and Mark Syms</i>	
• 17.B. Antiviral therapy versus control: Impact on recovery to normal or near-normal function	375
<i>Mitchell Ramsey and Mark Syms</i>	
• 17.C. Facial nerve decompression: Impact on recovery to normal or near-normal function	379
<i>Mark Syms and Mitchell Ramsey</i>	
18 Perioperative Antibiotics for Otologic Surgery	383
• 18.A. Perioperative systemic antibiotics versus control for myringoplasty: Impact on surgical site infections, graft success	383
<i>Jennifer J. Shin and Marlene Durand</i>	
• 18.B. Perioperative systemic antibiotics versus control for tympanoplasty with or without mastoidectomy: Impact on surgical site infections, graft success	388
<i>Jennifer J. Shin and Marlene Durand</i>	
• 18.C. Perioperative systemic antibiotics in patients with actively draining ears: Impact on postoperative infection, graft success	395
<i>Jennifer J. Shin and Marlene Durand</i>	
• 18.D. Perioperative systemic antibiotic prophylaxis for all types of otologic surgery combined: Impact on postoperative infection, graft success	399
<i>Jennifer J. Shin and Marlene Durand</i>	

Section IV Systematic Reviews in General Otolaryngology

19	Tonsillectomy in Adults	411
	• 19.A. Tonsillectomy for recurrent pharyngitis in adults: Impact on clinical improvement	411
	<i>Michael G. Stewart and Christopher Prichard</i>	
	• 19.B. Perioperative antibiotics versus placebo: Impact on postoperative symptom control.	417
	<i>Michael G. Stewart and Christopher Prichard</i>	
	• 19.C.i. Monopolar cautery versus cold dissection tonsillectomy: Impact on operating time, intraoperative blood loss, postoperative pain, return to normal diet, and/or postoperative bleeding.	423
	<i>James Denny and Wade Chien</i>	
	• 19.C.ii. Bipolar cautery versus cold dissection tonsillectomy: Impact on operating time, intraoperative blood loss, postoperative pain, return to normal diet, and/or postoperative bleeding.	431
	<i>James Denny and Wade Chien</i>	
	• 19.C.iii. Monopolar cautery versus ultrasonic/harmonic scalpel tonsillectomy: Impact on operating time, intraoperative blood loss, postoperative pain, return to normal diet, and/or postoperative bleeding	438
	<i>James Denny and Wade Chien</i>	
	• 19.C.iv. Radiofrequency/plasma (coblation) versus cold dissection tonsillectomy: Impact on operating time, intraoperative blood loss, postoperative pain, return to normal diet, and/or postoperative bleeding	442
	<i>James Denny and Wade Chien</i>	
20	Obstructive Sleep Apnea in Adults	447
	• 20.A. Continuous positive airway pressure versus placebo: Impact on sleepiness, quality of life, and driving performance in patients with obstructive sleep apnea.	447
	<i>David P. White and Roger S. Smith</i>	
	• 20.B. Continuous positive airway pressure versus uvulopalatopharyngoplasty in the treatment of obstructive sleep apnea.	452
	<i>David P. White and Roger S. Smith</i>	
	• 20.C. Uvulopalatopharyngoplasty versus oral appliance: Impact on apnea index and quality of life	458
	<i>Mary Beauchamp and Regina P. Walker</i>	
	• 20.D. Tongue suspension: Impact on quality of life, polysomnography, and excessive daytime sleepiness.	463
	<i>Kenny Pang and B. Tucker Woodson</i>	
21	Allergic Rhinitis	471
	• 21.A. Intranasal steroids versus nonsedating antihistamines: Impact on symptoms of seasonal allergic rhinitis.	471
	<i>Melissa Pynnonen and Jeffrey Terrell</i>	

• 21.B. Antihistamines versus montelukast versus antihistamine plus montelukast versus placebo for seasonal allergic rhinitis: Impact on symptoms of seasonal allergic rhinitis, and disease-specific quality of life	478
<i>Jeffrey Terrell and Melissa Pynnonen</i>	
22 Chronic Rhinosinusitis in Adults	489
• 22.A. Comparative oral antibiotic regimens: Impact on rates of cure, failure, relapse	489
<i>Stacey Gray, Jennifer J. Shin, and Ralph Metson</i>	
• 22.B. Oral antibiotic therapy for one month or longer: Impact on sinonasal symptoms, quality of life	494
<i>Stacey Gray, Jennifer J. Shin, and Ralph Metson</i>	
• 22.C. Aerosolized antibiotics: Impact on sinonasal outcomes	499
<i>Stacey Gray, Jennifer J. Shin, and Ralph Metson</i>	
• 22.D. Intranasal antifungal therapy: Impact on computed tomography, symptoms, quality of life, and endoscopy	503
<i>Stacey Gray, Jennifer J. Shin, and Ralph Metson</i>	
• 22.E.i. Endoscopic sinus surgery: Impact on disease-specific quality of life	507
<i>Jennifer J. Shin and Gregory W. Randolph</i>	
• 22.E.ii. Endoscopic sinus surgery: Impact on global quality of life . . .	513
<i>Jennifer J. Shin and Gregory W. Randolph</i>	
23 Adult Laryngopharyngeal Reflux	517
• 23.A. Proton pump inhibitor therapy versus placebo: Impact on symptom scores and laryngeal signs	517
<i>James Hartman</i>	
24 Unilateral Vocal Cord Paralysis	525
• 24.A. Unilateral vocal cord paralysis: Introductory overview	525
<i>Randall C. Paniello</i>	
• 24.B. Vocal fold injection: Impact on subjective and objective measures of voice	527
<i>Randall C. Paniello</i>	
• 24.C.i. Open medialization with implant: Impact on subjective and objective measures of voice	533
<i>Randall C. Paniello</i>	
• 24.C.ii. Medialization laryngoplasty alone versus medialization with arytenoid adduction: Comparative voice outcomes	540
<i>Randall C. Paniello and Jennifer J. Shin</i>	
• 24.D. Laryngeal reinnervation for unilateral vocal cord paralysis: Impact on voice outcomes	545
<i>Randall C. Paniello</i>	
• 24.E. Vocal fold injection versus medialization laryngoplasty: Impact on subjective and objective measures of voice	552
<i>Randall C. Paniello and Shivan Amin</i>	
• 24.F. Reinnervation versus no reinnervation: Impact on subjective and objective measures of voice	558
<i>Randall C. Paniello and Shivan Amin</i>	

Section V Systematic Reviews in Head and Neck Oncologic Surgery

25	Survival Analysis	567
	<i>Sandra S. Stinnett</i>	
26	Head and Neck Quality of Life Assessment and Outcomes Research	579
	<i>Richard Gliklich</i>	
27	Prophylaxis in Head and Neck Surgery	587
	• 27.A. One-day versus longer-course perioperative antibiotics: Impact on postoperative surgical-site infections	587
	<i>Jennifer J. Shin and Jonas T. Johnson</i>	
	• 27.B.i. Mechanical versus chemical prophylaxis in otolaryngologic surgery: Impact on thromboemboli	599
	<i>Jennifer J. Shin and Jonas T. Johnson</i>	
	• 27.B.ii. Compression versus subcutaneous heparin: Impact on postoperative or posttraumatic deep vein thrombosis, pulmonary emboli, and bleeding	604
	<i>Jennifer J. Shin and Jonas T. Johnson</i>	
28	Selective Neck Dissection for Upper Aerodigestive Tract Squamous Cell Carcinoma	623
	• 28.A. Supraomohyoid neck dissection versus modified radical neck dissection (type 3) for N0 oral cavity carcinoma: Chance of recurrence, chance of survival at 5 years	623
	<i>Jennifer J. Shin and Gregory W. Randolph</i>	
	• 28.B. Supraomohyoid neck dissection versus observation alone for stage I–II oral cavity carcinoma: Chance of recurrence, chance of survival at 2–3.5 years	627
	<i>Jennifer J. Shin and Gregory W. Randolph</i>	
	• 28.C. Supraomohyoid neck dissection for N0 oral cavity carcinoma: Chance of recurrence, chance of survival	629
	<i>Jennifer J. Shin and Gregory W. Randolph</i>	
	• 28.D. Supraomohyoid neck dissection as a staging procedure for N0 oral cavity carcinoma: Chance of recurrence or survival at 2 or more years with a negative versus positive specimen	632
	<i>Jennifer J. Shin and Gregory W. Randolph</i>	
	• 28.E. Lateral neck dissection versus type 3 modified radical neck dissection: Impact on survival, recurrence	635
	<i>Jennifer J. Shin and Gregory W. Randolph</i>	
	• 28.F. Sparing the spinal accessory nerve without versus with dissection of level V: Impact on postoperative quality of life	637
	<i>Jennifer J. Shin and Gregory W. Randolph</i>	
29	Oropharyngeal Squamous Cell Carcinoma	643
	• 29.A.i. Surgical resection with postoperative radiotherapy versus chemoradiation for stage III–IV oropharyngeal carcinoma: Impact on survival, recurrence	643
	<i>Richard Wein and Randal S. Weber</i>	

• 29.A.ii. Surgical resection with postoperative radiotherapy versus chemoradiation for oropharyngeal carcinoma: Impact on quality of life.	648
<i>Richard Wein and Randal S. Weber</i>	
• 29.B. Computed tomography scan versus orthopantomogram (Panorex) to assess mandibular invasion by oral cavity or oropharyngeal carcinoma: Positive and negative predictive values with respect to surgical or histologic confirmation	655
<i>Richard Wein and Randal S. Weber</i>	
30 Laryngeal Squamous Cell Carcinoma: Early-Stage Disease	661
• 30.A.i. Endoscopic resection versus radiation therapy for stage I–II glottic carcinoma: Impact on survival and local recurrence	661
<i>Yen-Lin Chen and Kian Ang</i>	
• 30.A.ii. Endoscopic resection versus radiation therapy for stage I–II glottic carcinoma: Impact on voice and quality of life.	667
<i>Yen-Lin Chen and Kian Ang</i>	
• 30.B. Open partial laryngectomy versus endoscopic laryngectomy for T1–2 glottic carcinoma: Impact on recurrence, salvage surgeries, and survival	674
<i>Ramon Franco and Jennifer J. Shin</i>	
• 30.C. Open partial laryngectomy with/without radiation therapy versus radiation therapy alone for T1–2 N0 supraglottic laryngeal carcinoma: Impact on survival and recurrence.	680
<i>Yen-Lin Chen and Kian Ang</i>	
• 30.D. Hyperfractionated versus conventional radiotherapy for T2 N0 laryngeal carcinoma: Impact on recurrence and survival	686
<i>Yen-Lin Chen and Kian Ang</i>	
31 Laryngeal Squamous Cell Carcinoma: Advanced Disease	691
• 31.A.i. Open partial laryngectomy versus total laryngectomy: Impact on disease-specific quality of life	691
<i>Ramon Franco, Jennifer J. Shin, and James Netterville</i>	
• 31.A.ii. Open partial laryngectomy versus total laryngectomy: Impact on global quality of life	696
<i>Ramon Franco, Jennifer J. Shin, and James Netterville</i>	
• 31.B.i. Total laryngectomy with postoperative radiation therapy versus induction chemotherapy with radiation therapy for stage III–IV laryngeal carcinoma: Impact on survival, recurrence	702
<i>Babar Sultan, Lori Wirth, and Merrill S. Kies</i>	
• 31.B.ii. Total laryngectomy with postoperative radiation therapy versus induction chemotherapy with radiation therapy for stage III–IV laryngeal carcinoma: Impact on quality of life, functionality.	708
<i>Babar Sultan, Lori Wirth, and Merrill S. Kies</i>	
• 31.C. Chemoradiation therapy versus radiation therapy alone for stage III–IV laryngeal carcinoma: Impact on survival, recurrence	716
<i>Lori Wirth, Babar Sultan, and Merrill S. Kies</i>	

32	Advanced Head and Neck Malignancy	723
	• 32.A. Adjuvant chemoradiotherapy versus adjuvant radiation therapy for high-risk head and neck cancer: Impact on survival, recurrence	723
	<i>Lori Wirth, Babar Sultan, and Merrill S. Kies</i>	
	• 32.B. Standard versus experimental cisplatin regimens for recurrent and/or metastatic head and neck squamous cell carcinoma: Impact on survival, response rate	730
	<i>Lori Wirth and Merrill S. Kies</i>	
	• 32.C. Chemoradiotherapy versus radiotherapy alone for locally advanced head and neck squamous cell carcinoma: Impact on locoregional response, disease control, overall survival	738
	<i>Lori Wirth and Merrill S. Kies</i>	
33	Papillary Thyroid Carcinoma	755
	• 33.A. Unilateral versus total thyroidectomy for low-risk papillary thyroid carcinoma: Impact on survival, recurrence	755
	<i>Christian Slough and Gregory W. Randolph</i>	
	• 33.B. Radioactive iodine versus no radioactive iodine as adjunctive treatment for low-risk papillary thyroid carcinoma: Impact on survival, recurrence	760
	<i>Christian Slough and Gregory W. Randolph</i>	
	Index	765